nuvaxovid - Search News

Order byBest matchMost fresh

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 2d

Infectious Disease Advisor · 2d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

PharmExec · 2d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

The FDA plans to limit access to covid vaccines. Here’s why that’s not all bad.

Covid vaccines will soon be required to go through more rigorous trials to ensure that they really are beneficial for people who aren’t at high risk.

MIT Technology Review · 7h

· 1d

FDA limits access to COVID-19 vaccine to older adults and other high-risk groups – a public health expert explains the new rules

wtvr · 19h

FDA advisory committee meets on COVID-19 vaccine after putting new restrictions on approvals

US FDA Advisers to Weigh Composition of COVID Vaccines for 2025-2026

Public health experts say that there is no certainty on which strains are going to be dominant.

· 1d

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

· 1h

FDA advisors for COVID shots left in the dark over how they’ll be regulated

Zacks Investment Research on MSN23h

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and regulatory updates were in focus.

23h

BMRN to Acquire Inozyme Pharma

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after BioMarin BMRN agreed to acquire Inozyme Pharma INZY. Meanwhile, other pipeline and

Novavax Shares Rise on FDA License Application Approval for Nuvaxovid

The biotechnology company said the FDA approved the biologics license application for Nuvaxovid to prevent Covid-19 in adults ages 65 and up and individuals ages 12 through 64 who have at least one underlying condition that puts them at high risk for severe outcomes from the coronavirus.

1don MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of

FDA’s Conditions on NVAX’s COVID-19 Jab

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.